0001640334-19-001293.txt : 20190703 0001640334-19-001293.hdr.sgml : 20190703 20190703170011 ACCESSION NUMBER: 0001640334-19-001293 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20190703 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20190703 DATE AS OF CHANGE: 20190703 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Inmune Bio, Inc. CENTRAL INDEX KEY: 0001711754 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 475205835 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38793 FILM NUMBER: 19942472 BUSINESS ADDRESS: STREET 1: 1224 PROSPECT STREET STREET 2: SUITE 150 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 8589643720 MAIL ADDRESS: STREET 1: 1224 PROSPECT STREET STREET 2: SUITE 150 CITY: LA JOLLA STATE: CA ZIP: 92037 8-K 1 inmb_8k.htm FORM 8-K inmb_8k.htm

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 3, 2019

 

INMUNE BIO INC.

(Exact name of registrant as specified in charter)

 

Nevada

 

001-38793

 

47-5205835

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number)

 

Identification No.)

 

1224 Prospect Street, Suite 150, La Jolla, CA 92037

(Address of Principal Executive Offices) (Zip Code)

 

(858) 964 3720

(Registrant’s Telephone Number, Including Area Code)

 

Not Applicable

(Former Name or Former Address, If Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

 

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock

INMB

NASDAQ

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 
 
 
 

Item 7.01 Regulation FD Disclosure

 

On July 3, 2019, INmune Bio, Inc. (the “Company”) issued a press release (the “Release”) announcing that R.J. Tesi, M.D., the Company’s co-founder and Chief Executive Officer, presented at the Maxim Group’s conference on Alzheimer’s disease on June 26, 2019 in New York City.

 

A copy of the Release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. Exhibits 99.1 shall not be deemed “filed” for purposed of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act.

 

Item 9.01 Financial statements and Exhibits

 

(d) Exhibits.

 

Exhibit Number

 

Description

 

 

 

99.1

 

Press Release dated July 3, 2019

 

 

 2

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

INMUNE BIO INC.

 

Date: July 3, 2019

By:

/s/ David Moss

 

David Moss

 

Chief Financial Officer

 

 

 3

 

EX-99.1 2 inmb_ex991.htm PRESS RELEASE inmb_ex991.htm

EXHIBIT  99.1

 

INmune Bio Co-Founder and CEO Presents at Maxim Group’s Conference on Alzheimer’s Disease

 

La Jolla, CA – July 3, 2019 – INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced that R.J. Tesi, M.D., the company’s co-founder and CEO, presented at the Maxim Group’s conference on Alzheimer’s disease on June 26 in New York. During his presentation, Dr. Tesi addressed how INmune Bio’s drug candidate XPro1595 targets microglial activation and neuroinflammation to treat Alzheimer’s, which may be a key driver in the disease. 

 

During the conference, titled “Alzheimer's Disease – What's Next? Treating Alzheimer's in a Post-Amyloid World,” Dr. Tesi discussed INmune Bio’s novel approach to treating Alzheimer’s  with XPro1595, a second generation selective inhibitor of soluble TNF (tumor necrosis factor) to combat neuroinflammation and microglial activation. The novel biomarker-directed clinical trial design uses inflammatory biomarkers to select patients and determine treatment effects.

 

“I was delighted to showcase INmune Bio’s development program with XPro1595 in Alzheimer’s disease,” said Dr. Tesi. We believe that our Phase I clinical trial supported by the Alzheimer’s Association Part-the-Cloud Award is a positive step in exploring if reversing microglial activation and neuroinflammation will have an impact on this devastating disease.”

 

INmune Bio will begin enrolling patients into Xpro1595’s Phase I clinical trial in the coming weeks.

 

About INmune Bio, Inc.

INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (NK) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid-derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.

 

INmune Bio Contact:

David Moss, CFO

(858) 964-3720

DMoss@INmuneBio.com

 

Media Contact:

Antenna Group

Holly Dugan

(201) 465-8019

INmuneBio@AntennaGroup.com